Synergy CHC Corp. (NASDAQ:SNYR) has run into a serious balance-sheet problem. The consumer health and wellness company, known for brands in the nutrition and supplement space, disclosed in an August 2026 regulatory filing that it had received a notice of default on its term …
●UpstreamBio reported a net loss of about $39.7 million reflecting its clinicalInvestmentand a Phase 3 development strategy targeting 2027.
● neffy is a needle-free epinephrine nasal spray for severe allergic reactions, an alternative to traditional auto-injectors.
● Senti's lead candidate, SENTI-202, is a gene-circuit CAR-NK cell therapy aimed at relapsed or refractory acute myeloid leukemia.
Tvardi Therapeutics (NASDAQ:TVRD) is at the stage every clinical biotech must eventually reach: the point where pipeline promise meets the hard arithmetic of cash and catalysts. The company, which develops orally available small-molecule STAT3 inhibitors, updated investors in mid-August 2026 with aBusinessreview that laid …
● The company reaffirmed its 2026 and 2027 guidance.
HCW Biologics (NASDAQ:HCWB) is an immunotherapy company developing novel biologics aimed at chronic inflammation and autoimmune diseases. The company reported second-quarter 2026 results with an update on an early-stage program, following a period of building progress.
Keros Therapeutics (NASDAQ:KROS) has undergone a wrenching reset, discontinuing development of a lead cardiopulmonary drug after safety concerns and restructuring around a different candidate. Understanding what the company is now focused on, and what it discontinued, is essential to assessing the shares.
MoonLake Immunotherapeutics (NASDAQ:MLTX) has been generating the kind of late-stage clinical data that can define a biotech's future, reporting positive Phase 3 results for its lead drug across multiple inflammatory diseases. With a differentiated therapy and a string of successful trials, investors are watching …
● The company reported 30-day results from the CGUARDIANS II clinical trial of its CGuard Prime implant.